BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

Phanes Therapeutics begins patient dosing in clinical study of mavrostobart in combination with chemotherapy: San Diego Wednesday, May 28, 2025, 18:00 Hrs [IST] Phanes Therapeutic ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...